3 Slides Suggesting Gilead Sciences May Be Unstoppable

Image source: Gilead Sciences.

This is a multi-decade growth opportunity

HCV is a long-tail growth opportunity, and Gilead Sciences is just cracking the surface. Despite Gilead noting that there are in the neighborhood of 4 million treatable HCV patients within the United States, it's only been able to treat approximately 300,000 of them with a Sovaldi-based therapy (Harvoni is a cocktail drug comprised of Sovaldi and ledipasvir) between Dec. 2013 and Sept. 2015. If Gilead and physicians are only able to ramp up production and treatment to around 200,000 people per year, it would mean, even with competition, that Gilead would have until the mid-2020's before its U.S. HCV gravy train began to slow.

Of course, that's when the real patient potential could kick in. According to the World Health Organization, there are an estimated 180 million people worldwide with HCV. In emerging and still developing markets Gilead's margins would be relatively low to even non-existent. However, there's still plenty of time for emerging and developing markets to grow into profitable regions for Gilead. Ultimately, Gilead's HCV franchise looks to have a multi-decade growth opportunity on its hands, and I personally wouldn't be surprised if annual HCV sales topped $20 billion before the end of the decade.

In addition to having an enormous patient pool that could take decades to fully reach, Gilead is always finding ways to improve its HCV dominance.

Image source: Gilead Sciences.

Innovation in HCV makes unseating Gilead very difficult

First, Gilead brought Sovaldi to market in late 2013, providing sustained virologic response rates of 90% or better in genotype 1 HCV patients (genotype 1 comprises about 70% of all cases). Shortly thereafter in 2014 it introduced Harvoni which offered an even more favorable treatment profile and also high SVR rates of 90% or higher. Now, Gilead is working on two experimental HCV therapies, one of which looks to cement itself as potentially untouchable.

As reported last year, Gilead's Sovaldi in combination with velpatasvir delivered ridiculously strong virologic clearance over 12 weeks in four pan-genomic ASTRAL studies. In ASTRAL 1 the SVR12 rate was a whopping 99% in genotypes 1, 2, 4, 5, and 6, and 99% in ASTRAL 2 for genotype 2 patients. In ASTRAL 3, which examined genotype 3, arguably the toughest genotype to cure, SVR12 hit 95%. The sustained virologic response was even an impressive 94% in genotypes 1 through 6 with Child-Pugh class B, implying these patients had serious liver disease which often carries a two-year survival rates of less than 60%. Gilead has filed for approval of this combination therapy and has a PDUFA decision date of June 28, 2016.

Gilead is also developing a triplet drug comprised of Sovaldi, velpatasvir, and a protease inhibitor. The belief is that adding the protease inhibitor could further improve virologic clearance in genotype 3 HCV patients, reduce the already-small number of patients who fail to exhibit disease clearance in other genotypes, and most importantly, reduce the treatment timeframe to just eight weeks for most, or all, genotypes (with the exception of the patients who failed HCV clearance). Milligan noted concern about toxicity tied to protease inhibitors, but he appeared encouraged with the potential for moving the bar one notch higher.

Could anyone really challenge Gilead's pan-genomic HCV therapy? Perhaps the only contender is Merck , which is the process of developing its own triplet. Merck's triplet demonstrated 90%+ SVR clearance rates in its clinical studies, but more importantly it did so in just eight weeks for genotypes 1, 2, and 3. There's further testing to be done here, but Merck's triplet is looking like the only near-term option that has any chance of giving Gilead a run for its money in HCV.

Image source: Gilead Sciences.

A pipeline and product portfolio worth marveling

Lastly, Gilead has plenty of options it can turn to beyond just HCV and HIV, even if they do make up the bulk of the company's current revenue.

Gilead's pipeline currently consists of 26 clinical programs, but as you can see to the left, there are far more waiting in the wings to hit preclinical trials. This is a deep pipeline spanning multiple indications, and it suggests that Gilead could easily have multiple therapeutic indications to rely on in the coming years.

For instance, Gilead is developing an intriguing oncology portfolio of products that could potentially deliver billions of dollars in sales. Expansion of Zydelig's label into frontline indolent non-Hodgkin lymphoma and frontline chronic lymphocytic leukemia could result in the drug approaching blockbuster status. Zydelig is currently in late-stage studies for frontline CLL and midstage studies for frontline iNHL.

We also need to keep our eyes on Gilead's work in liver diseases beyond HCV. Hepatitis B affects an even greater number of people than HCV, and nonalcoholic steatohepatitis, or NASH, affects around 2% of the U.S. adult population in its most severe form. Gilead is looking at treating NASH with a kitchen sink approach, tossing anti-LOXL2 antibody simtuzumab, a drug designed to target liver fibrosis, GS-4997 which is targeted at reducing inflammation, and GS-9674, an oral FXR agonist which is designed to handle metabolic complications tied to the disease, at NASH.

This is a deep pipeline that should continue to pay big dividends.

Gilead may be unstoppable

All companies have possible pitfalls and risks, but it's difficult to find many weaknesses with Gilead Sciences.

It's always possible that prescription drug reform strips its HCV program of its lucrative pricing power, but that seems highly unlikely, as such a move could drive innovation overseas. It's also possible that competition could weigh on HCV sales, but the market is certainly big enough for a few effective entrants. The way I see it, Gilead looks poised to continue to grow numerous aspects of its pipeline and product portfolio. Long-term and value investors taking note.

The next billion-dollar iSecret

The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .

The article 3 Slides Suggesting Gilead Sciences May Be Unstoppable originally appeared on

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.The Motley Fool owns shares of and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More